Jim Simons Tcr2 Therapeutics Inc. Transaction History

Renaissance Technologies LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$1.0 - $1.62 $248,486 - $402,547	-248,486 Reduced 35.84%	444,800 $667,000
Q4 2022 Feb 13, 2023	SELL	$0.83 - $1.44 $11,299 - $19,604	-13,614 Reduced 1.93%	693,286 $692,000
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $82,584 - $166,500	-44,400 Reduced 5.91%	706,900 $1.27 Million
Q2 2022 Aug 12, 2022	SELL	$2.11 - $2.94 $1.46 Million - $2.03 Million	-691,300 Reduced 47.92%	751,300 $2.18 Million
Q1 2022 May 13, 2022	BUY	$2.4 - $4.71 $1.32 Million - $2.59 Million	550,700 Added 61.74%	1,442,600 $3.98 Million
Q4 2021 Feb 11, 2022	BUY	$4.58 - $8.34 $3.2 Million - $5.82 Million	698,100 Added 360.22%	891,900 $4.16 Million
Q3 2021 Nov 12, 2021	BUY	$8.44 - $18.35 $273,456 - $594,540	32,400 Added 20.07%	193,800 $1.65 Million
Q2 2021 Aug 13, 2021	BUY	$16.41 - $24.71 $211,689 - $318,759	12,900 Added 8.69%	161,400 $2.65 Million
Q1 2021 May 13, 2021	BUY	$20.38 - $34.07 $3.03 Million - $5.06 Million	148,500 New	148,500 $3.28 Million
Q4 2020 Feb 10, 2021	SELL	$19.0 - $32.63 $1.29 Million - $2.21 Million	-67,700 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$13.1 - $20.69 $440,160 - $695,184	33,600 Added 98.53%	67,700 $1.38 Million
Q2 2020 Aug 13, 2020	SELL	$6.51 - $16.85 $111,972 - $289,820	-17,200 Reduced 33.53%	34,100 $524,000
Q1 2020 May 14, 2020	BUY	$6.01 - $16.01 $308,313 - $821,313	51,300 New	51,300 $397,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.